MDxHealth maintains its 2026 revenue guidance of $137M, expecting 27-30% growth. MDxHealth also confirms its view of driving progress toward a 10% adjusted EBITDA margin run rate exiting 2026.
Bullish
MDxHealth achieved 20% full-year revenue growth to $107.9M and a 128% increase in liquid-based test volume in Q4. MDxHealth also expanded gross margins to 64.5% for the full year.
Bearish
MDxHealth faced increased net losses and operating expenses in Q4, with a 53% rise in adjusted EBITDA loss. Additionally, MDxHealth's tissue-based test volume decreased by 5% over the prior year period.